Aicardi Goutières Syndrome Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Targeted Therapies and Rising Disease Awareness | DelveInsight

Posted on
by

Aicardi Goutières Syndrome Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Targeted Therapies and Rising Disease Awareness | DelveInsight
The market dynamics for Aicardi Goutières Syndrome (AGS) are evolving steadily due to increasing awareness of rare genetic interferonopathies, improvements in genetic diagnostic capabilities, and growing research activities focused on targeted immunomodulatory therapies. Additionally, the development of emerging therapies such as IMSB301 and advancements in JAK inhibitor-based treatment approaches are expected to further support the AGS market growth during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Aicardi Goutières Syndrome (AGS) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Aicardi Goutières Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Aicardi Goutières Syndrome Market

  • The market size for Aicardi Goutières Syndrome in the 7MM is expected to increase significantly by 2036 owing to the launch of emerging therapies and advancements in rare disease diagnostics.

  • The United States accounted for the highest AGS market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.

  • According to Orphanet (2024), more than 500 cases of AGS have been reported in the literature to date.

  • According to Hunter’s Hope (2025), roughly 400 cases of AGS were known as of 2014, and just over 120 cases had been reported in medical literature. The early-onset form affects around 20% of babies affected by AGS.

  • An article by the National Health Service (2021) highlighted that AGS is the most common monogenic interferonopathy, with an estimated prevalence in England of 1 in 110,000.

  • As per a study conducted by Shoaff et al. (2022), AGS affects less than 1 in 100,000 newborns.

  • Leading AGS companies, such as ImmuneSensor Therapeutics and others, are developing novel therapies to improve outcomes in AGS patients.

  • The promising AGS therapies in clinical trials include IMSB301 and other targeted interferonopathy therapies.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/aicardi-goutieres-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Aicardi Goutières Syndrome Market

Increasing Awareness and Improved Genetic Diagnosis:Growing recognition of interferonopathies and advancements in genetic testing technologies are improving the diagnosis of AGS globally. Early identification of TREX1, RNASEH2B, RNASEH2C, RNASEH2A, SAMHD1, ADAR, IFIH1, and RNU7-1 mutations is supporting earlier intervention and disease management.

Growing Interest in Targeted Immunomodulatory Therapies:Therapeutic approaches such as JAK inhibitors, immune-modulation therapies, antiretrovirals, and anti-IFN-alpha antibodies are being increasingly explored to manage AGS symptoms and underlying inflammation pathways.

Emergence of Novel Pipeline Therapies:The AGS pipeline, although limited, is witnessing progress with therapies such as IMSB301, a novel orally available cGAS inhibitor developed by ImmuneSensor Therapeutics. The therapy aims to suppress cytokine production and prevent pathological inflammation associated with AGS.

Aicardi Goutières Syndrome Competitive Landscape

The AGS pipeline includes emerging therapies such as IMSB301 (ImmuneSensor Therapeutics) and others focused on modulating interferon signaling pathways and reducing inflammatory responses. IMSB301 is a novel orally available small molecule designed to inhibit the cGAS enzyme and suppress disease-causing inflammation in AGS and other Type I interferonopathies.

These therapies are expected to address the major unmet need in AGS, where no approved disease-modifying therapies currently exist and treatment remains largely supportive.

Discover more about therapies set to grab major Aicardi Goutières Syndrome market share @Aicardi Goutières Syndrome Treatment Landscape

Recent Developments in the Aicardi Goutières Syndrome Market

  • In February 2026, ImmuneSensor Therapeutics announced that it dosed the first patient with IMSB301 in a Phase Ib clinical study in Australia involving genetically defined AGS and other Type I interferonopathies patients.

  • In November 2024, the US FDA granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to IMSB301 for the treatment of cGAS-driven Type I interferonopathy, AGS.

What is Aicardi Goutières Syndrome?

Aicardi Goutières Syndrome (AGS) is a rare hereditary leukodystrophy and monogenic interferonopathy characterized by severe neurological dysfunction and systemic inflammation. Symptoms usually appear within the first six months of life, although some cases may present later. AGS is associated with developmental delay, microcephaly, seizures, dystonia, feeding difficulties, and skin lesions such as chilblains. The disease often results in profound disability and can be life-threatening.

Aicardi Goutières Syndrome Epidemiology Segmentation

The AGS epidemiology section provides insights into the historical and current AGS patient pool and forecasted trends across the 7MM. The AGS market report offers epidemiological analysis for the study period 2022–2036 segmented into:

  • Total Incident and Diagnosed Prevalent Cases of AGS

  • Type-specific Cases of AGS (early-onset and late-onset)

  • Mutation-specific Cases of AGS

  • Country-specific AGS Patient Population

Scope of the Aicardi Goutières Syndrome Market Report

  • Therapeutic Assessment: AGS current and emerging therapies

  • AGS Market Dynamics: Key Market Forecast Assumptions and Market Outlook

  • Key Companies: ImmuneSensor Therapeutics and others

  • Key Therapies: IMSB301 and others

  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, AGS Market Access and Reimbursement

To know more about Aicardi Goutières Syndrome companies working in the treatment market, visit @Aicardi Goutières Syndrome Clinical Trials and Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services